UNSPSC 51123105: Droxicainide hydrochloride

This classification denotes an antiarrhythmic agent with the molecular formula C16H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91801A0812, chemically known as droxicainide hydrochloride, (+/-)-, but more generally known as droxicainide hydrochloride, which bears US NIH Compound Identifier 3060807. European Medicines Agency schedules droxicainide hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06418MIG.

Most nations, for tariff purposes, schedule droxicainide hydrochloride under HS 29333999. SMILES: CC1CCCC(C1NC(=O)C2CCCCN2CCO)C.CL.

UNSPSC 51123105 Droxicainide hydrochloride, a Commodity code, represents emergency and critical-care pharmaceuticals that state and local government health and public safety agencies procure for trauma response, acute care delivery, and emergency medical services. Recent solicitations show state and local buyers sourcing advanced life support medications—including vasopressors, inotropes, and cardiac agents—through sealed bid, cooperative purchasing, and market-research channels. The City of Tampa Fire Rescue, Minnesota's multistate cooperative purchasing alliance (MMCAP), and the Texas Health and Human Services Commission represent the range of issuing bodies: municipal fire departments and emergency services, state health agencies, and cooperative purchasing vehicles serving multiple jurisdictions. Work under this code includes supply of FDA-compliant pharmaceuticals meeting cGMP and Drug Supply Chain Security Act standards, with vendor delivery commitments, expiration-date warranties, replacement liability, and compliance with OSHA Hazard Communication and federal accessibility standards.

Recent activity spans the South (Florida), Upper Midwest (Minnesota, serving Oregon), and Texas. The City of Tampa issued an IFB (Bid No. 26P00188) due April 8, 2026, for advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem—estimated value $40,000—with a five-percent bid discount for Small Local Business Enterprise participation. MMCAP posted an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, effective July 1, 2026, with evaluations weighted 75 percent on price competitiveness and vendor performance penalties ranging from $200 to $1,500 per violation. The Texas HHS Commission issued an RFI (HHS0017013) in early April 2026 seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and group purchasing organization channels—a preliminary market-research phase likely to precede formal procurement. Vendors should expect firm pricing requirements, delivery commitments within ten days, minimum one-year product warranties, and comprehensive insurance coverage including $5,000,000 general liability.